Equity (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Schedule of Equity

	Three Months Ended June 30,
	Common Stock			Other Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock			Non- controlling Interests		Total
($ and shares in millions except per share amounts)	Shares	Par Value								Shares	Cost
Balance at April 1, 2021	3,577	$	1,788	$	39,613	$	48,888	$	(6,622)	1,046	$	(56,722)	$	94	$	27,039
Net income attributable to Merck & Co., Inc.	—	—		—		1,545		—		—	—		—		1,545
Other comprehensive income, net of taxes	—	—		—		—		1,545		—	—		—		1,545
Cash dividends declared on common stock ($0.65 per share)	—	—		—		(1,656)		—		—	—		—		(1,656)
Treasury stock shares purchased	—	—		—		—		—		3	(239)		—		(239)
Spin-off of Organon & Co.	—	—		4,643		—		449		—	—		(1)		5,091
Share-based compensation plans and other	—	—		(217)		—		—		(5)	279		—		62
Net income attributable to noncontrolling interests	—	—		—		—		—		—	—		1		1
Balance at June 30, 2021	3,577	$	1,788	$	44,039	$	48,777	$	(4,628)	1,044	$	(56,682)	$	94	$	33,388
Balance at April 1, 2022	3,577	$	1,788	$	44,275	$	56,252	$	(4,369)	1,049	$	(57,063)	$	70	$	40,953
Net income attributable to Merck & Co., Inc.	—	—		—		3,944		—		—	—		—		3,944
Other comprehensive income, net of taxes	—	—		—		—		42		—	—		—		42
Cash dividends declared on common stock ($0.69 per share)	—	—		—		(1,759)		—		—	—		—		(1,759)
Share-based compensation plans and other	—	—		(160)		—		—		(5)	293		—		133
Net income attributable to noncontrolling interests	—	—		—		—		—		—	—		5		5
Balance at June 30, 2022	3,577	$	1,788	$	44,115	$	58,437	$	(4,327)	1,044	$	(56,770)	$	75	$	43,318

	Six Months Ended June 30,
	Common Stock			Other Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock			Non- controlling Interests		Total
($ and shares in millions except per share amounts)	Shares	Par Value								Shares	Cost
Balance at January 1, 2021	3,577	$	1,788	$	39,588	$	47,362	$	(6,634)	1,047	$	(56,787)	$	87	$	25,404
Net income attributable to Merck & Co., Inc.	—	—		—		4,724		—		—	—		—		4,724
Other comprehensive income, net of taxes	—	—		—		—		1,557		—	—		—		1,557
Cash dividends declared on common stock ($1.30 per share)	—	—		—		(3,309)		—		—	—		—		(3,309)
Treasury stock shares purchased	—	—		—		—		—		3	(239)		—		(239)
Spin-off of Organon & Co.	—	—		4,643		—		449		—	—		(1)		5,091
Share-based compensation plans and other	—	—		(192)		—		—		(6)	344		—		152
Net income attributable to noncontrolling interests	—	—		—		—		—		—	—		8		8
Balance at June 30, 2021	3,577	$	1,788	$	44,039	$	48,777	$	(4,628)	1,044	$	(56,682)	$	94	$	33,388
Balance at January 1, 2022	3,577	$	1,788	$	44,238	$	53,696	$	(4,429)	1,049	$	(57,109)	$	73	$	38,257
Net income attributable to Merck & Co., Inc.	—	—		—		8,254		—		—	—		—		8,254
Other comprehensive income, net of taxes	—	—		—		—		102		—	—		—		102
Cash dividends declared on common stock ($1.38 per share)	—	—		—		(3,513)		—		—	—		—		(3,513)
Share-based compensation plans and other	—	—		(123)		—		—		(5)	339		—		216
Net income attributable to noncontrolling interests	—	—		—		—		—		—	—		2		2
Balance at June 30, 2022	3,577	$	1,788	$	44,115	$	58,437	$	(4,327)	1,044	$	(56,770)	$	75	$	43,318